Capsid Tropism Screening Platforms Market Outlook From 2026 To 2030: Key Growth Factors And Future Opportunities
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Capsid Tropism Screening Platforms Market Growth Potential: How Will Market Size Shift Through 2030?
The market size for capsid tropism screening platforms has seen rapid expansion in recent years. This market is expected to increase from $0.74 billion in 2025 to $0.85 billion in 2026, at a compound annual growth rate (CAGR) of 14.2%. The development observed in previous periods can be linked to increasing investment in gene therapy research, growing demand for viral vector optimization, adoption of flow cytometry and sequencing technologies, rising focus on personalized medicine, and expansion of pharmaceutical and biotech R&D infrastructure.
The capsid tropism screening platforms market is anticipated to experience substantial growth in the coming years. It is projected to expand to $1.45 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 14.4%. This projected growth can be attributed to several factors, including the increasing application of AI-driven capsid tropism analysis, the broader adoption of high-content imaging and microfluidics, a rising demand for single-cell sequencing and sophisticated screening platforms, the expansion of contract research organizations (CROs), and the enhanced integration of multiplex assay and digital PCR technologies. Furthermore, key trends for the forecast period include the increasing uptake of high-throughput screening platforms, an escalating demand for next-generation sequencing solutions, the wider integration of flow cytometry technologies, an expansion in the available assay kits and reagent offerings, and a heightened focus on gene therapy and vaccine development applications.
Get A Free Sample Report With In-Depth Market Insights:
Capsid Tropism Screening Platforms Market Growth Catalysts And Demand Drivers
The heightened demand for targeted gene therapies is projected to fuel the expansion of the capsid tropism screening platforms market throughout the forecast period. These therapies focus on delivering therapeutic genetic material precisely to specific cells or tissues, aiming to correct, alter, or substitute flawed genes linked to illnesses. Several factors contribute to this escalating demand, such as the increasing occurrence of genetic and rare diseases, progress in vector engineering technologies, and greater investment in precision medicine strategies designed to enhance treatment effectiveness while reducing unintended side effects. Capsid tropism screening platforms are crucial in gene therapy development, as they facilitate the systematic assessment and selection of viral vectors that exhibit ideal tissue and cell specificity. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, the number of gene therapies in Phase III clinical trials increased by 10% in the fourth quarter of 2023, representing the first quarterly increase since the third quarter of 2022. Consequently, the growing need for targeted gene therapies is a significant driver for the growth of the capsid tropism screening platforms market.
Capsid Tropism Screening Platforms Market Breakdown By Product Type And Application
The capsid tropism screening platforms market covered in this report is segmented –
1) By Technology: High-Throughput Screening, Next-Generation Sequencing, Flow Cytometry, Other Technologies
2) By Product Type: Assay Kits, Reagents, Instruments, Software, Services
3) By Application: Gene Therapy Development, Vaccine Development, Drug Discovery, Other Applications
4) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations, Other End-Users
Subsegments:
1) By High-Throughput Screening: Cell-Based Screening, Biochemical Screening, High-Content Screening, Automated Screening, Label-Free Screening
2) By Next-Generation Sequencing: Short-Read Sequencing, Long-Read Sequencing, Targeted Sequencing, Whole-Genome Sequencing, Single-Cell Sequencing
3) By Flow Cytometry: Conventional Flow Cytometry, Spectral Flow Cytometry, Imaging Flow Cytometry, Cell Sorting, Mass Cytometry
4) By Other Technologies: Microfluidics-Based Screening, High-Content Imaging, Mass Spectrometry, Polymerase Chain Reaction And Digital Polymerase Chain Reaction, Immunoassay-Based Platforms
Capsid Tropism Screening Platforms Market Trends Shaping Long-Term Demand
Leading companies operating within the capsid tropism screening platforms market are forging strategic alliances to create innovative high-throughput and barcoded adeno-associated virus screening solutions. These strategic partnerships stimulate the expansion of the capsid tropism screening platforms market by facilitating the collaborative advancement of sophisticated adeno-associated virus screening technologies, diversifying product ranges, and expediting gene therapy research and its market entry. For example, in August 2025, PackGene Biotech Inc., a US-based biotechnology company, finalized a strategic licensing agreement with the Children’s Medical Research Institute (CMRI), an Australia-based independent organization, to commercialize barcoded high-throughput adeno-associated virus capsid screening kits. These kits empower researchers to swiftly assess multiple adeno-associated virus capsid variants simultaneously, leveraging a barcode system and next-generation sequencing. The aim of this collaboration is to accelerate gene therapy development through optimized capsid selection and improved access to advanced screening instruments.
Capsid Tropism Screening Platforms Market Key Participants And Competitive Landscape
Major companies operating in the capsid tropism screening platforms market are Sarepta Therapeutics Inc., Voyager Therapeutics Inc., Bluebird Bio Inc., Sangamo Therapeutics Inc., REGENXBIO Inc., MeiraGTx Holdings plc, Dyno Therapeutics Inc., 4D Molecular Therapeutics Inc., Asklepios BioPharmaceutical Inc., PackGene Biotech Inc., Creative Biolabs Inc., VectorBuilder Inc., uniQure N.V., Homology Medicines Inc., Capsida Biotherapeutics Inc., LogicBio Therapeutics Inc., Capsigen Inc., GeneMedi Inc., Spark Therapeutics Inc., Creative Biogene Inc.
View The Full Capsid Tropism Screening Platforms Market Report:
Capsid Tropism Screening Platforms Market Geographic Analysis: Where Is Demand Rising Fastest?
North America was the largest region in the capsid tropism screening platforms market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the capsid tropism screening platforms market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
